Idiotype vaccination for Non-Hodgkin lymphoma

  • Protocol
  • Intervention

Authors


Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

In order to evaluate the therapeutical benefit of idiotype vaccination in the treatment of NHL we will particularly analyse overall survival (OS) as the primary endpoint; as well as progression-free survival (PFS), response rate, treatment-related mortality, adverse events and quality of life as secondary endpoints. We will analyse these outcome parameters critically and systematically with respect to different vaccine formulations, dosages or time schedules in the experimental arm and placebo or no other treatment in the control arm.